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Anti-nucleosomeAbstract Background: Systemic lupus erythematosus (SLE) is the most heterogeneous chronic
autoimmune disease; it is characterized by the presence of auto reactive B and T cells, responsible
for the aberrant production of a broad and heterogeneous group of autoantibodies. Recent studies
using various detection methods have demonstrated the elevations of circulating DNA in SLE
patients.
Aim of the study: The current study aimed to measure cell-free DNA (cf-DNA) in SLE patients
as a potential tool to predict disease activity and treatment follow up.
Subjects and methods: 52 of SLE patients with age ranging from 10 to 48 years were randomly
selected and 25 healthy subjects with age and gender matched with the patients were included as a
control group. Thorough clinical examination stressing on the central nervous system, vascular,
renal, rash, musculoskeletal, mucocutaneous manifestations, and fever was done for patients.
The following investigations were done: Complete blood count (CBC), kidney function tests,
C-reactive protein (CRP), routine autoantibodies for autoimmune diseases, complements (C3 &
C4), anti-nucleosome antibodies and cf-DNA by real time PCR (RT-PCR).
Results: The levels of anti-double stranded DNA (anti-dsDNA), anti-nucleosome Ab, and
cf-DNA were signiﬁcantly increased in SLE patients compared to controls. The cf-DNA level
was correlated to markers of disease severity namely CRP and anti-nucleosome. A signiﬁcant reduc-
tion in levels of cf-DNA, anti-nucleosome Ab and anti-dsDNA was noticed after therapy.
80 O.M. Hendy et al.Conclusion: Our ﬁndings support that the measurement of cf-DNA appears to be a useful mar-
ker in addition to laboratory tests used in SLE diagnosis. High correlation with markers of disease
severity suggesting its role in disease pathogenesis and decreasing its level after therapy makes it to
be a marker of treatment follow-up.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Circulating cell-free DNA (cf-DNA) has been found in the
plasma of human subjects. It has been extensively studied over
the past few decades. Supported by theory and observation,
two major sources of cf-DNA have been postulated: ﬁrst, frag-
mented DNA released as a consequence of cell death (apopto-
sis/necrosis of blood and tissue cells) and, second, active
metabolic secretion of DNA from cells. Considerable research
efforts had been made on the use of cf-DNA as a biomarker in
cancer diagnosis [1].
In various pathologic conditions, qualitative and quantita-
tive changes in circulating DNA have also been shown, such as
mutations, deletions, methylations and microsatellite aberra-
tions which are distinct from those in benign conditions, and
thus may be useful in the diagnosis of cancer [2]. Only small
amounts of serum or plasma DNA have been observed in
healthy individuals, whereas high concentrations had been
described in patients with various malignancies and in those
with several benign diseases, such as infections, sepsis, trauma,
stroke, and autoimmune diseases [3,4]. Because most of these
disorders are associated with increased rates of cell death
events, from apoptosis or necrosis, these mechanisms are con-
sidered to be the main sources for circulating DNA. Active
release of DNA by lymphocytes is thought to be of minor
relevance [4,6].
For many years, free DNA research has been focused on
examining the level of free DNA in autoimmune diseases like
rheumatoid arthritis [7], systemic sclerosis [8] and primary
Sjogren’s syndrome [9]. In case of rheumatoid arthritis, Leon
et al. [7] had discovered higher concentrations of free DNA
in both plasma and synovial ﬂuid than in healthy subjects
while the increasing intensity was correlated with the symptom
severity and the level of the tissue damage. Unlike them,
Mosca et al. [8] did not establish the signiﬁcant difference in
cf-DNA concentration in patients with systemic sclerosis and
in healthy subjects, but based on the cf-DNA level they could
make a difference between patients with active disease and
those with the inactive one.
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease that has the potential of affecting multiple organ systems,
including the skin, muscles, bones, lungs, kidneys, as well as
the cardiovascular and central nervous systems [10,11].
SLE can cause various tissue inﬂammation and damage in a
chronic manner and cell death [12]. Cell death has been
regarded as an important event in the pathogenesis of SLE,
as it leads to the release of antigens, such as nucleic acids,
for immune complex formation, and that DNA-antibody com-
plexes in the circulation are one of the hallmarks of SLE.
DNA-antibody complexes may trigger a cascade of immune
responses against the bodily tissues of the SLE patients [13,14].SLE was one of the pathological conditions reported to be
associated with the presence of circulating DNA nearly
59 years ago [15]. Since then, studies using various detection
methods have demonstrated the elevations of circulating
DNA in SLE patients [16,17]. Investigating whether and to
what degree ﬂuctuations in cf-DNA levels in patients with
SLE might correspond to disease severity was the goal of many
investigations [8,17]. The most recent data seem to exclude
measuring cf-DNA as an inexpensive, simple and quick tool
to assess disease activity in patients with SLE [9,17].
The application of molecular biologic techniques has
allowed the molecular characterization of cf-DNA in certain
pathologic and physiologic conditions. Various methods have
been established for the measurement of circulating DNA.
Quantiﬁcation of DNA in plasma and serum by real-time
PCR is widely accepted as standard and detects all kinds of
free and protein bound circulating DNA [5]. However, there
have been very few studies reporting the detailed biological
characterization of circulating DNA in SLE [18]. The
extremely variable clinical manifestations and the absence of
effective tests to monitor disease activity present a challenge
for clinical management.
1.1. Aim of the study
The current study aimed to measure the circulating cell free
DNA (cf-DNA) as a potential tool to predict disease severity
and treatment follow up in patients with SLE.2. Patient and methods
Fifty-two of SLE patients attending the Menouﬁya and Al
Azhar University Hospitals between February 2013 and
September 2014 were included in the study. Samples were
taken from patients who fulﬁlled at least four of the
American College of Rheumatology criteria for the diagnosis
of SLE [19]. They were 40 females and 12 males with age rang-
ing from 10–48 years, mean ± SD (28.42 ± 11.43). Twenty-
ﬁve healthy subjects (18 female and 7 males) age and gender
matched with the patients were included in the study as a
control group.
All patients were subjected to: full history and thorough
clinical examination stressing on the central nervous system,
vascular, renal, rash, musculoskeletal, mucocutaneous mani-
festations, and fever. Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) was calculated for all patients, a
score of 8 or more was deﬁned as active disease at the begin-
ning of the study [20]. Fourteen patients had SLEDAI score
of 6 or less and hence were considered inactive SLE; the
remaining 38 were categorized to have active SLE disease.
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Patients with any concurrent disease, positive viral markers,
malignant tumors, history of previous blood transfusion, other
autoimmune diseases, primary anti-phospho-lipid syndrome,
chronic or acute inﬂammatory diseases were excluded from
the study.
3. Therapy follow-up
Cytotoxic drugs; cyclophosphamide, azathioprine, or
mycophenolate mofetil were given to SLE patients according
to the therapy protocol. In 38 of the 52 SLE patients after
therapy follow-up, blood was collected at an interval of
1–13 months and re-analyzed in the same way. All study pro-
cedures were approved by the Ethics Committee of the faculty
college of Medicine. All subjects were informed orally about
the procedures and the aim of the study and gave written con-
sent to participate. The work has been carried out in accor-
dance with the World Medical Association (declaration of
Helsinki) for experiments in humans.
3.1. Blood sampling
Ten ml of blood was collected under complete aseptic
conditions, and divided into 3 vacutainer tubes: 2 ml on
EDTA-anticoagulated blood for complete blood count,
3.2 ml on plain tube for serology, auto-antibody determina-
tion, 1.8 ml on 3.2% of Na citrate for Lupus anticoagulant.
The remaining 3 mL was put on EDTA-anti-coagulated blood
for plasma separation by centrifugation of fresh EDTA blood
at 4 C at 1600g for 10 min. The plasma fraction was trans-
ferred carefully and centrifuged in a second step at 4 C and
1600g for 5 min to remove any cellular debris. The supernatants
were stored at 20 C until used for cf-DNA measurement.
Routine laboratory investigations were done, as Complete
blood count (CBC) on Sysmix-KN21automatic cell counter
(Japan), kidney function tests on Integra 400 (Roche-
Diagnostics, Germany) and CRP on Elecyces-20 (Roche-
Diagnostic, Germany).
Antinuclear antibody (ANA) was measured by indirect
immunoﬂuorescence assay (IIF) on mouse kidney and stomach
slides (Immco-Diagnostics, USA). Detection of auto-
antibodies of SSA (Ro), SSB (La), anti-Sm and anti-RNP
was done by ELISA semi-quantitative technique using
INOVA Diagnostics (San Diego-USA). Anti-double stranded
DNA (anti-dsDNA) titer was done by ELISA technique using
INOVA Diagnostics (San Diego-USA).
Anti-Cardiolipin antibodies (APL IgM & APL IgG) were
detected by APhL IgG and IgM ELISA Kit (Louisville
diagnostics-USA). Lupus anticoagulant was done by the
ACTICLOT diluted partial thrombin time (dPTT) test
(AMERICAN DIAGNOSTICA GmbH). It is used for the
qualitative diagnostic determination of LA in patient plasmas.
Determination of complement C3 and C4 levels in serum
was done on automated Elecyces-20 (Roche-Diagnostic,
Germany).
Anti-nucleosome antibodies’ (IgG) detection was done by
ELISA kit (D-TEK, Belgium, Germany). Principle: brieﬂy,
after incubation of diluted serum sample in the micro-well
coated with puriﬁed nucleosomes. If anti-nucleosome antibodywas present in the serum, it binds to speciﬁc antigens.
Unbound or excess antibodies were removed by washing,
and HPR-conjugate rabbit antibodies against human IgG were
added to wells to form antigen antibody complexes. After
incubation and second wash to remove excess conjugate, the
TMB/substrate solution was added. If the enzyme activity
was present, it generates blue reaction which is measured
colorimetric by an ELISA plate reader at 450 nm. The
absorbance was directly proportional to anti-nucleosome anti-
body concentration in serum sample.3.2. Detection of plasma cell free DNA (cf-DNA) by real time
PCR
DNA was extracted from 400 ll plasma using QIA amp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. The ﬁnal elution was performed
in 50 ll of AE buffer of the QIA amp DNA blood mini kit,
and the eluted DNA was stored at 20C until further
processing.
For analyzing cf-DNA, the GAPDH housekeeping gene
has been used with forward 50-CCCCACACACATGCACTT-
ACC-30 and reverse 50-CCTAGTCCCAGGGCTTTGATT-30
primers, and 50-MGB-TAGGAAGGACAGGCAAC–VIC-30
as the probe [21] has been applied. Five ml of DNA elution
was used as a template for the real-time PCR analysis. The
PCR was performed using the ABI PRISM 7000 Sequence
Detection System (Applied Biosystems, ABI). The real-time
PCR was carried out in 25 ll of total reaction volume contain-
ing 5 ll of DNA, 12.5 ll of TaqMan Universal PCR Master
Mix, four primers, and two probes using two minute incuba-
tion at 50 C. The reaction was processed by an initial
denaturation step at 95 C for 10 min and 40 cycles of 1 min
at 60 C and 15 s at 95 C. For the multiplex TaqMan ampli-
ﬁcation of the concentration of primers and probes was opti-
mized. The optimal concentration of the primers and probes
for duplex real-time PCR is 0.6 lM for each primer and
0.4 lM for each probe [22]. The positive reaction was detected
by the accumulation of a ﬂuorescent signal. The cycles
required for the ﬂuorescent signal to cross the threshold are
deﬁned as cycle threshold (CT).
The CT values can also be converted into quantities accord-
ing to standard curves generated by dilution of human
genomic DNA with a known concentration for generating
the standard curves as follows: Each reaction included a cali-
bration curve of 6.6 ng to 6.6 pg genomic DNA made from 4
serial dilutions of purchased human genomic DNA (0.2 g/L
in 10 mmol/L Tris–HCl, 1 mmol/L EDTA, pH 8.0),
(Roche Diagnostics GmbH-Germany) plus 2 known dilutions
(50 and 500 pg DNA) used as controls in all experiments
[23,24].3.3. Statistical analysis
All mean values were expressed as mean ± standard deviation
(SD). The distribution of each continuous variable was exam-
ined statistically for normality. Variables normally distributed
were compared using Student t-test. In contrast, variables not
normally distributed were compared using the Mann–Whitney
test. Spearman correlation test was used to assess the
Table 2 Comparison between the laboratory data of patients
and controls.
Parameters SLE Patients Control group p value
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signiﬁcance of the recorded OR, a two-sided p< 0.05 was con-
sidered to be signiﬁcant. All statistical analyses were per-
formed using Computer program SPSS version 20.
(n= 52)
(M± SD)
(n= 25) (M± SD)
Age (years) 28.42 ± 11.43 32.58 ± 14.22 >0.05
Female (No. %) 40 (76.9%) 18 (72%) >0.05
ESR (mm/h) 91.42 ± 34.8 11.23 ± 6.75 <0.001
Hb (g/dL) 10.53 ± 1.72 13.25 ± 1.18 <0.05
TLC (·109/L) 6.22 ± 3.14 9.54 ± 3.65 <0.05
Platelet count
(·109/L)
131.2 ± 54.1 276.1 ± 41.72 <0.01
CRP (mg/L) 9.53 ± 6.72 0.28 ± 0.03 <0.01
C3 (mg/dl) 48.22 ± 11.03 88.61 ± 9.11 <0.01
C4 (mg/dl) 19.32 ± 4.71 26.81 ± 7.65 >0.05
Anti-dsDNA
(IU/ml)
38.52 ± 7.24 2.73 ± 1.51 <0.001
Anti-
nucleosome Ab
(IU/ml)
56.41 ± 29.26 9.81 ± 2.37 <0.001
cf-DNA(ng/mL) 16.31 ± 2.58 5.47 ± 1.94 <0.014. Results
Female predominance was evident as expected, with a female/-
male ratio of 3.3:1. The mean age for all patients’ was
28.42 years. The mean illness duration was 8.32 years.
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) was 7.31. The frequency of clinical manifestations
was photosensitivity (67.3%), arthralgia/myalgia (59.6%),
renal manifestations (46.2%), cutaneous manifestations
(40.4%), arthritis (32.6%) and serositis (11.5%), as percentage
of total patients. Raynaud’s phenomenon (9.6%), neurological
manifestations (9.6%), and hematological manifestations
(7.69%) were the least common clinical manifestations.
The main autoantibodies detected were ANA (96.2%),
anti-dsDNA (80.8%), anti-Ro (48.1%), anti-RNP (32.7%),
and anti-La (26.9%). Anti-Cardiolipin IgM (21.2%) anti-
Cardiolipin IgG (15.4%) and lupus anticoagulants (13.5%)
were the least detected antibodies (Table 1).
While comparing the demographic data of patient and con-
trol groups, there was no statistical signiﬁcant difference
regarding age and sex (p value >0.05) for both. In contrast,
the laboratory investigations showed that, the hemoglobin
(Hb) concentration, total leukocytic counts (TLC), platelets
and C3 were signiﬁcantly low in SLE patients compared to
health controls (p value <0.05, <0.05, <0.01) respectively,
while, ESR, CRP, anti-dsDNA, anti-nucleosome Ab, and cf-
DNA were signiﬁcantly higher in SLE patients compared to
controls (p values were <0.001, <0.01, <0.05, <0.001,Table 1 Characteristic data of the SLE patients.
Characteristics of SLE patients (N= 52)
Female/male (ratio) 40/12 (3.3:1)
Age (years) 28.42 ± 11.43
Disease duration/years (M± SD) 8.32 ± 6.14
SLEDAI (M± SD) 7.31 ± 5.26
Clinical Manifestations:
 Arthralgia/myalgia
 Arthritis
 Renal manifestations
 Hematological manifestations
 Neurological manifestations
 Cutaneous manifestations
 Photosensitivity
 Serositis
 Raynaud’s phenomenon
Number (%)
31 (59.6%)
17 (32.6%)
24 (46.2%)
4 (7.69%)
5 (9.6%)
21 (40.4%)
35 (67.3%)
6 (11.5%)
5 (9.6%)
Auto-antibodies:
 Anti-dsDNA
 ANA
 Anti-Ro
 Anti-La
 Anti-Sm
 Anti-RNP
 Anti-Cardiolipin IgM
 Anti-Cardiolipin IgG
 Lupus anticoagulant
Number (%)
42 (80.8%)
50 (96.2%)
25 (48.1%)
14 (26.9%)
10 (19.2%)
17 (32.7%)
11 (21.2%)
8 (15.4%)
7 (13.5%)<0.001 and <0.01) respectively. The C4 levels were decreased,
but did not reach statistical difference (Table 2).
Regarding the correlation study, there was a signiﬁcant
negative correlation between cf-DNA levels and ANA, anti-
dsDNA level, and C3 (r= 0.45, p< 0.05; r= 0.38,
p< 0.05; r= 57, p< 0.01) respectively. In contrast a posi-
tive correlation was found between cf-DNA level and CRP,
anti-nucleosome Ab serum level (r= 0.41, p< 0.05;
r= 0.36, p< 0.05) respectively. No correlation was found
between cf-DNA level and each of age, gender, SLEDAI score
or C4 (p> 0.05 for each) (Table 4).
Comparison between the laboratory data of SLE patients
before and after therapy revealed a statistically signiﬁcant
reduction in antibodies after therapy. Anti-nucleosome Ab
was reduced from a pretreatment mean of 56.41 IU/ml to
a post treatment mean of 21.56 IU/ml (p value <0.05).
Anti-dsDNA was reduced from a pretreatment mean of
38.52 IU/ml to a post treatment mean of 13.25 IU/ml (p value
<0.05). Cf-DNA was reduced from a pretreatment mean of
16.31 ng/mL to a post treatment mean of 7.15 ng/mL (p value
<0.01) (Table 3 and Fig. 1).Table 3 Correlation of cf-DNA level to patient’s data
(n= 52).
Parameters cf-DNA
r p value Sign. value
Age 0.07 >0.05 NS
Gender 0.13 >0.5 NS
SLEDAI score 0.19 >0.05 NS
ANA 0.45 <0.05 S
Anti-dsDNA 0.38 <0.05 S
CRP 0.41 <0.05 S
C3 0.57 <0.01 HS
C4 0.13 >0.05 NS
Anti-nucleosome Ab 0.36 <0.05 S
Table 4 Comparison between the laboratory data of SLE
patients before and after treatment.
Parameters SLE Patients
before therapy
(n= 52)
(M± SD)
After
therapy
(n= 38)
(M± SD)
p
value
Anti-nucleosome
Ab (IU/ml)
56.41 ± 29.26 21.56 ± 7.42 <0.05
Anti-dsDNA (IU/ml) 38.52 ± 7.24 13.25 ± 2.14 <0.05
cf-DNA (ng/mL) 16.31 ± 2.58 7.15 ± 2.11 <0.01
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The ﬂuctuations in cell free DNA (cf-DNA) levels in patients
with SLE which might correspond to disease severity were
the goal of many investigations. This study was aimed to ana-
lyze cf-DNA in a group of SLE patients with different disease
status and have clinical manifestations, to assess the ﬂuctua-
tion of cf-DNA level in relation to the course of the disease
progression and medical treatment.
In the present study, the serum level of cf-DNA was signif-
icantly higher in SLE patients than in the healthy controls.
This result was in accordance with the studies carried out by
Atamaniuk et al. [17], Breeitbach et al. [25], Suzan et al. [26].
The higher level of cf-DNA in SLE patients could result from
ineffective clearance of apoptotic and necrotic cells [27], the
release of DNA from neutrophils extracellular traps and its
impaired degradation was also described in SLE [28].
Additionally, the neutrophil extracellular traps are implicated
in sterile inﬂammation and could contribute to auto-
inﬂammatory conditions, vascular inﬂammation and atheroge-
nesis [13].
The serum level of C3 was signiﬁcantly lower in our SLE
patients than in the controls and in spite of C4 decrease in
SLE patients, it did not reach a statistical signiﬁcance. SLE
is usually associated with complement consumption, resulting
in low serum levels of C3 and C4 levels. This may be due to
a concomitant phenomenon involved in the generation and
increase of cf-DNA [13].Figure 1 Mean plasma levels of cf-DNA inIn an attempt to associate between cf-DNA concentrations
and complement components in SLE, we observed that,
although no correlation was found between cf-DNA and C4,
there is an inverse correlation between the cf-DNA level and
C3, in SLE patients. This result is not surprising since SLE
associated complement consumption, resulting in low levels
of C3 and C4, could be a concomitant phenomenon involved
in the generation and increase of cfDNA [13].
In contrast, Suzan et al. [26] found that the complement
factors C3 and C4 correlated positively with cfDNA concen-
trations in both study populations. Barteloni et al. [9] did
not ﬁnd any correlation between cf-DNA and complement
components C3 and C4. It was also reported that ﬂuctuations
in complement and anti-dsDNA-antibodies did not predict
disease ﬂares which led the authors to the conclusion that
alternative biomarkers should be tested. There was a good
rationale to use complement activation products as a marker
for disease activity. However, available studies have conﬂicting
results, showing correlation of complement component and
the disease activity in some but not in other studies. Some of
this may result from methodological differences, such as the
use of plasma versus serum and the differences of disease
activity [29].
A positive correlation of cfDNA with CRP in our SLE
patients could be a further hint regarding the involvement of
cfDNA in inﬂammatory responses. In contrast, Suzan et al.
[26], found no relation between cf-DNA and CRP levels in
SLE patients, and explained that it could be due to the fact
that the serum level of CRP was hardly changed during SLE
ﬂare [13]. Therefore, a simultaneous rise of cf-DNA and
CRP in the case of high disease activity could be expected.
In the current study, anti-dsDNA level was signiﬁcantly
higher in SLE patients than in controls. Increasing lines of evi-
dence suggested that dsDNA plays an important role in the
pathogenesis of SLE as it can cause inﬂammatory responses
[30]. Additionally, anti-dsDNA was negatively correlated sig-
niﬁcantly with the serum level of cf-DNA in the studied SLE
patients. This was in agreement with the result of Isenberg
et al. [31] study, who mentioned a well-documented phe-
nomenon is that titer of anti dsDNA antibodies dropped in
ﬂare up of SLE disease [32]. Also, Macanovic et al. [33]
reported that, the development of nephritic syndrome in someSLE patients before and after treatment.
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These results could be explained by the fact that accelerated
tissue deposition during active state leads to the decrease of
Ab titer in the circulation.
In our study, there was a negative correlation between cf-
DNA and ANA levels in SLE patients. This could be explained
by the possibility that the high amount of antibody bound
nucleic acid could impede the detection of cf-DNA in the cir-
culation either by the formation of complexes or by clearance
from the circulation [34].
Moreover, in the current study, the anti-nucleosome Ab
was signiﬁcantly higher in SLE patients compared to controls,
and its level is positively correlated with cf-DNA. This ﬁnding
is in agreement with that of Amoura and Piette [35], who
reported the prominence of nucleosomes which circulate at
high levels in some autoimmune diseases such as SLE; it has
been speculated that highly accelerated rates of apoptosis,
and/or abnormal sites or abnormal processing of apoptotic
cells could lead to autoantibody production. Also, nucleo-
somes may elicit the production of interleukin-6 and stimula-
tion of lympho-proliferation and IgG synthesis by splenic B
cells. This could result in a polyclonal activation that triggers
both a speciﬁc (nucleosome driven) and nonspeciﬁc antibody
production [36].
In attempts to assess ﬂuctuation of the level of cf-DNA dur-
ing the course of SLE, we compared the serum level of cf-DNA
in relation to SELADI score. There was no signiﬁcant correla-
tion observed between the serum level of cf-DNA and
SELADI score in our SLE patients. This goes in accordance
with the results of the study carried out by Barteloni et al.
[9] and Suzan et al. [26], who stated that, no correlation was
detected between the serum level of cf-DNA and SELADI
score in their studies. Based on their ﬁnding, Atamaniuk
et al. [17] excluded that cf-DNA is a suitable marker for
SLE activity. However, the SELADI is used as a common
activity marker for SLE but it is also known that this param-
eter does not necessarily reﬂect the severity of disease activity.
SELADI score only rates the presence or absence of items and
not the grade of severity in most of its items [37]. Hence, the
lack of correlation is not surprising.
Moreover, the medical evaluation of disease usually con-
sists of a combination of SELADI score, patient symptoms,
laboratory parameters, and a signiﬁcant correlation with cf-
DNA. Furthermore, a signiﬁcant reduction of the serum levels
of cf-DNA, anti-dsDNA, and anti-nucleosome after speciﬁc
drugs therapy for SLE disease indicates the prognostic value
of cf-DNA in SLE disease.
6. Conclusion
The cf-DNA levels were signiﬁcantly higher in SLE patients
compared to healthy controls. The positive relationship
between its level and markers of diseases severity may suggest
its role in disease pathogenesis and decreasing its level after
therapy make it to be a possible marker of treatment follow-
up. Further studies on a larger patient population are still
needed to conﬁrm these results.
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